Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause)

A total of 1,461,300 shares were delivered in connection with the 23rd Series Stock Acquisition Rights from 1 March to 18 March 2026, reducing the number of unexercised rights from 107,738 to 93,125. During the period, 14,613 rights were exercised, representing 10.74% of the total number issued.

Worth reading
66In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1461300
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Large-scale exercise of the 23rd Series Stock Acquisition Rights with an exercise price adjustment clause

発行・処分する株式数

Shares delivered since the beginning of the month: 1,461,300 shares (1,461,300 new shares and 0 treasury shares transferred)

Terms of the stock acquisition rights
Exercise price
Subject to an exercise price adjustment clause. Exercise prices during the period were ¥105.8, ¥95.7, ¥97.6, ¥100.3 and ¥98.5
Number of Stock Acquisition Rights
Total number issued: 136,125 rights (14,613 rights, or 10.74% of the total number issued); unexercised balance as of the end of the previous month: 107,738 rights; current unexercised balance: 93,125 rights
Most recent equity financing
15 December 2025: Issuance of the 23rd Series Stock Acquisition Rights (with an exercise price adjustment clause) (the issue price and amount are Not disclosed in this document)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalLarge-scale exercise of the 23rd Series Stock Acquisition Rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofShares delivered since the beginning of the month: 1,461,300 shares (1,461,300 new shares and 0 treasury shares transferred)
Total number of issued shares70,890,000 shares (as of the end of the previous month, including 12,229 treasury shares) → Not disclosed
Exercise priceSubject to an exercise price adjustment clause. Exercise prices during the period were ¥105.8, ¥95.7, ¥97.6, ¥100.3 and ¥98.5
Number of Stock Acquisition RightsTotal number issued: 136,125 rights (14,613 rights, or 10.74% of the total number issued); unexercised balance as of the end of the previous month: 107,738 rights; current unexercised balance: 93,125 rights
Most recent equity financing15 December 2025: Issuance of the 23rd Series Stock Acquisition Rights (with an exercise price adjustment clause) (the issue price and amount are Not disclosed in this document)
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company states that this announcement is to report the large-scale exercise of the 23rd Series Stock Acquisition Rights from 1 March to 18 March 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori